Eligibility Criteria

General inclusion and exclusion criteria for clinical trial participation

Bronchial Asthma

We are currently conducting studies for patients with moderate-to-severe asthma that is not well controlled despite regular maintenance treatment.

✓ Inclusion criteria✗ Exclusion criteria
✓ Age 12–70 years (depending on the study)✗ Severe uncontrolled comorbidities (cardiac, metabolic, psychiatric)
✓ Asthma diagnosis for at least 6–12 months✗ Exacerbation or respiratory infection in the last 4–6 weeks
✓ Documented reversible airway obstruction (bronchodilator response)✗ Active smoker or smoking history >10 pack-years
✓ Stable dose of ICS ± LABA (maintenance therapy) for at least 3 months✗ Pregnancy or breastfeeding
✓ FEV₁ ≥ 30–80% predicted (varies by study)✗ Other significant pulmonary disease (COPD, cystic fibrosis, pulmonary fibrosis)
✓ At least 1 exacerbation requiring systemic steroids in the past 12 months✗ Current or recent use of other biologic therapy for asthma
✓ Signed informed consent✗ Known allergy to study drug components

COPD

We are conducting studies for patients with moderate to very severe COPD who experience frequent exacerbations despite regular inhaler use.

✓ Inclusion criteria✗ Exclusion criteria
✓ Age 40–80 years✗ Asthma as primary diagnosis
✓ COPD diagnosis for at least 1 year (per GOLD criteria)✗ Exacerbation or respiratory infection in the last 4 weeks
✓ Smoking history ≥ 10 pack-years (current or former)✗ Active pulmonary rehabilitation (<4 weeks)
✓ FEV₁/FVC < 0.70 and FEV₁ 20–80% predicted✗ Continuous oxygen therapy >12 hours/day
✓ On stable triple (ICS+LABA+LAMA) or dual inhaled therapy for ≥3–6 months✗ Active or past malignancy
✓ ≥ 2 moderate or ≥ 1 severe exacerbation in the past 12 months✗ Unstable cardiovascular disease
✓ CAT score ≥ 10–15 (symptomatic COPD)✗ Other significant pulmonary disease

Bronchiectasis

We are participating in a Phase III study (AIRTIVITY™) of a novel oral tablet (cathepsin C inhibitor) for patients with bronchiectasis who experience recurrent flare-ups.

✓ Inclusion criteria✗ Exclusion criteria
✓ Age ≥ 12 years (adolescents must weigh ≥35 kg)✗ Cystic fibrosis
✓ CT-confirmed bronchiectasis✗ Active mycobacterial (NTM) infection or tuberculosis
✓ Chronic sputum production (able to produce a sputum sample)✗ Lung surgery or transplantation in the past 12 months
✓ ≥ 2 pulmonary exacerbations requiring antibiotics in the past 12 months✗ Pregnancy or breastfeeding
✓ Post-BD FEV₁ ≥ 30% predicted✗ Allergic bronchopulmonary aspergillosis (ABPA)
✓ Signed informed consent✗ Continuous oxygen therapy >12 hours/day

Specific criteria vary by protocol. Only the study doctor can determine your eligibility after a thorough assessment. Contact us — we are happy to help.

Questions about eligibility?

Contact us — we'll assess whether a study is suitable for you.

Contact us →
Call us Email us